Pioglitazone Improves Survival In Patients With Cancer: The Hypothesis
Pioglitazone is currently the only thiazolidinedione approved by regulatory agencies worldwide for the treatment of type 2 diabetes mellitus (T2DM). The use of pioglitazone in patients with T2DM has been limited because earlier studies showed moderate weight gain and an increased incidence of hea...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
VBZ
2015-12-01
|
| Series: | Endocrine Oncology and Metabolism |
| Subjects: | |
| Online Access: | http://eom.hdeo.eu/wp-content/uploads/2017/02/vol1-iss1-2Saboo.pdf |